A monoclonal antibody to a human mdr1 multidrug resistance gene product, and uses
CA 2132540 C · Owner: The Board Of Trustees Of The University Of Illinois · Inventors: Roninson, Igor B.; Mechetner, Eugene
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Hybridomas (termed "UIC2 hybridoma", ATCC Accession No. HB11207 and "UIC2/A hybridoma", ATCC Accession No. HB11287) producing monoclonal antibody (termed "UIC2 mAb") directed against an extracelluar domain of a cell surface P-glycoprotein antigen associated with multidrug resistance in primate cells was produced by fusing a human myeloma cell with a spleen cell derived from a Balb/c mouse immunized with syngeneic 3T3 fibroblasts previously transfected with the isolated human mdrl cDNA. UIC2 mAb thus produced, as, well as fragments and recombinant derivative thereof may be, used to detect and isolate multidrug resistant primate cells and human mdrl gene products, and to reverse multidrug …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 17, 1993 and granted October 7, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 17, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 17, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.